{"slideshow_credits": null, "snippet": "The court said the company could still benefit from patent protection for the multiple sclerosis drug, dealing a blow to makers of generic drugs.", "abstract": "Supreme Court rules that Teva Pharmaceutical Industries could continue to benefit from patent protection from its multiple sclerosis drug Copaxone, sending case back to federal appeals court for revaluation; decision deals blow to generic competitors.", "section_name": "Business Day", "print_page": "2", "document_type": "article", "byline": {"person": [], "organization": "REUTERS", "original": "By REUTERS", "contributor": ""}, "web_url": "http://www.nytimes.com/2015/01/21/business/supreme-court-rules-in-favor-of-teva-in-copaxone-patent.html", "lead_paragraph": "The court said the company could still benefit from patent protection for the multiple sclerosis drug, dealing a blow to makers of generic drugs.", "headline": {"main": "Supreme Court Rules in Favor of Teva Over Patent for Multiple Sclerosis Drug", "print_headline": "Supreme Court Rules for Teva on Multiple Sclerosis Patent"}, "_id": "54beb66c38f0d826e07c1104", "word_count": "387", "multimedia": [], "pub_date": "2015-01-21T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "organizations", "value": "Teva Pharmaceutical Industries Ltd", "is_major": "Y", "rank": "1"}, {"name": "organizations", "value": "Supreme Court (US)", "is_major": "Y", "rank": "2"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "3"}, {"name": "subject", "value": "Multiple Sclerosis", "is_major": "N", "rank": "4"}, {"name": "subject", "value": "Inventions and Patents", "is_major": "Y", "rank": "5"}, {"name": "glocations", "value": "Israel", "is_major": "N", "rank": "6"}], "blog": [], "subsection_name": null, "type_of_material": "News"}